Taking No Chances in Neuroprotection: Pharmos Applies a Precise Phase III Protocol
This article was originally published in Start Up
Executive SummaryNeuroprotection has been something of a clinical tar pit--many compounds have gone into the clinic but none have emerged. It's hard to know what's going on inside someone else's head, much less measure changes induced by any agent. Pharmos feels it has learned from the missteps of other companies, and so has structured a highly precise Phase III protocol to give its drug candidate dexanabinol the best chance at success.
You may also be interested in...
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.
RxMP Therapeutics LLC is working to resolve excessive diffuse bleeding that is often associated with trauma, and also with certain orthopedic and cardiovascular surgeries. The start-up believes it can successfully treat excessive diffuse bleeding with particles produced from the membranes of red blood cells that have been freeze-dried and then, literally, blown to bits.